Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Priothera Limited is managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct art units and involve 3 distinct examiners. This distribution indicates that while the technology is focused, the specific applications are being evaluated by different sets of eyes. The busiest examiner, COLEMAN, BRENDA LIBBY, is responsible for 1 pending action, showing an even workload distribution across the 3 examiners.
The use of 2 distinct art units for 3 pending office actions suggests some overlap in the technical classification of the company's filings. However, the fact that 3 distinct examiners are involved means that each of the 3 pending office actions will likely receive a unique interpretation. Practitioners must tailor their responses to the individual preferences of each examiner rather than assuming a uniform approach across the portfolio.
With 3 pending office actions, Priothera Limited has a moderate level of activity that requires careful coordination. The relationship of pending actions to examiners for the busiest official, COLEMAN, BRENDA LIBBY, confirms that no single examiner is handling multiple cases for the company. This lack of examiner concentration means that success in one matter may not necessarily influence the outcomes of the others.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| §112 only | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COLEMAN, BRENDA LIBBY | 1 | 74.9% | +15.5% |
| SHOWALTER, ALEXANDER KEITH | 1 | 54.4% | +26.3% |
| KUCHARCZK, JED A | 1 | 80.2% | +16.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17263440 | AGENT FOR INHIBITING RECURRENCE OF HEMATOLOGICAL MALIGNANCY IN PATIENTS WHO HAVE UNDERGONE HEMATOPOIETIC STEM CELL TRANSPLANTATION | KUCHARCZK, JED A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18066883 | METHODS OF TREATMENT WITH S1P RECEPTOR MODULATORS | SHOWALTER, ALEXANDER KEITH | 60d overdue |
| 18869588 | TREATMENT OF CANCER WITH S1P RECEPTOR AGONISTS | COLEMAN, BRENDA LIBBY | — |
| 17263440 | AGENT FOR INHIBITING RECURRENCE OF HEMATOLOGICAL MALIGNANCY IN PATIENTS WHO HAVE UNDERGONE HEMATOPOIETIC STEM CELL TRANSPLANTATION | KUCHARCZK, JED A | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18869588 | TREATMENT OF CANCER WITH S1P RECEPTOR AGONISTS | COLEMAN, BRENDA LIBBY | — | §112 | Non-Final OA | — | Pending | Nov 26, 2024 |
| 18066883 | METHODS OF TREATMENT WITH S1P RECEPTOR MODULATORS | SHOWALTER, ALEXANDER KEITH | 1629 | §103 | Final Rejection | 60d overdue | Pending | Dec 15, 2022 |
| 17263440 | AGENT FOR INHIBITING RECURRENCE OF HEMATOLOGICAL MALIGNANCY IN PATIENTS WHO HAVE UNDERGONE HEMATOPOIETIC STEM CELL TRANSPLANTATION | KUCHARCZK, JED A | 1623 | §103 | Non-Final OA | — | Pending | Jan 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial